Hong Kong, 3 October 2026 – A little-known cholesterol-related blood marker called lipoprotein(a), or Lp(a), is gaining attention as cardiologists increasingly recommend that adults test it at least once in their lifetime to better understand their inherited risk of heart attack and stroke.
Unlike conventional LDL cholesterol, Lp(a) levels are largely determined by genetics and remain relatively stable throughout life. Diet and exercise can improve overall cardiovascular health, but they generally do not significantly change Lp(a) itself.
That makes the blood test particularly useful for identifying risk that may otherwise remain hidden.
The American Heart Association says about one in five people worldwide has elevated Lp(a), often without symptoms. A standard cholesterol panel does not usually include Lp(a), meaning patients need to specifically request the test from their healthcare professional. www.heart.org
Why Lp(a) Matters
Lipoprotein(a) resembles LDL cholesterol but carries an additional protein called apolipoprotein(a).
When levels are high, Lp(a) can contribute to plaque build-up, inflammation and blood clots inside arteries, increasing the risk of cardiovascular disease.
Current guidance considers 125 nmol/L, or about 50 mg/dL, and above to be elevated. At substantially higher levels, cardiovascular risk can rise further. www.heart.org
The important point is that Lp(a) adds risk independently of many traditional factors.
Large cohort studies have found that higher Lp(a) concentrations are associated with greater risk of atherosclerotic cardiovascular disease, including coronary heart disease and stroke, even after accounting for other risk factors. PubMed
One Test May Be Enough for Most Adults
Because Lp(a) is primarily inherited and does not fluctuate significantly over time, most people may only need to have it measured once.
That is one reason new cardiovascular guidance has increasingly moved towards broader screening rather than limiting testing to people who already have heart disease.
A high reading does not mean someone will inevitably develop cardiovascular disease.
Instead, it helps doctors build a more complete risk profile alongside blood pressure, LDL cholesterol, diabetes, smoking status, family history and body weight.
For some patients, particularly those with unexpectedly early heart disease in the family, the result may help explain risk that conventional cholesterol testing does not capture.
Lifestyle Still Matters Even if Lp(a) Does Not Change
One potentially confusing aspect of Lp(a) is that healthy lifestyle changes generally do not lower the marker itself.
That does not mean they are ineffective.
If Lp(a) is elevated, reducing other modifiable cardiovascular risks becomes even more important.
Regular physical activity, avoiding smoking, maintaining a healthy weight, managing blood pressure and keeping LDL cholesterol under control can reduce overall cardiovascular risk even if the inherited Lp(a) concentration remains unchanged.
At present, there is no widely approved medicine specifically designed solely to lower Lp(a), although some existing lipid-lowering treatments can reduce it modestly and several targeted therapies are under development. www.heart.org
The Ledger Asia Insights
For Asia, the growing attention on Lp(a) is important because cardiovascular disease remains one of the region’s largest healthcare burdens.
The shift towards earlier testing reflects a broader change in medicine: moving from treating heart disease after symptoms appear towards identifying inherited and metabolic risk decades earlier.
This has implications not only for patients, but also for healthcare systems and investors.
More widespread Lp(a) screening could increase demand for diagnostic testing, preventive cardiology and lipid-management services. If targeted medicines currently in development prove effective, they could also create a significant new treatment category.
The risk, however, is overinterpreting a single test result.
Lp(a) should not be viewed in isolation or treated as a definitive prediction of future disease. Cardiovascular risk is shaped by multiple factors, including age, blood pressure, LDL cholesterol, diabetes, smoking and family history.
The more useful role of Lp(a) is as an additional piece of information — particularly for people whose inherited risk may not be obvious from standard screening.
For individuals, the practical message is straightforward: because Lp(a) is largely genetic and usually stable, a simple blood test performed once can provide information that may remain relevant for decades. In preventive medicine, that makes it an unusually efficient way to uncover a risk factor that many people may otherwise never know they carry.
